Insmed Inc Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS Conference Call
Llamada en conferencia Insmed Inc
Insmed Inc Conference call or earnings call will be held on 05-sep-2017 via an 800 number (toll-free). During the earnings conference call's session Insmed Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Insmed Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
Insmed is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. Our lead product candidate is ARIKAYCE(TM), or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. Our earlier stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil, a vasodilator of pulmonary arterial vascular beds. We believe INS1009 may offer a differentiated product profile with therapeutic potential in pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), sarcoidosis, and severe refractory asthma.Leer más Llamada en conferencia